VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

MVA-CHIKV

Vaccine Information

Vaccine Ontology ID: VO_0004666
Type: Recombinant vector vaccine
Status: Research
Host Species for Licensed Use: Baboon
Preparation: The highly attenuated poxvirus vector modified vaccinia virus Ankara (MVA) was used to express the CHIKV C, E3, E2, 6K, and E1 structural genes (termed MVA-CHIKV) (García-Arriaza et al., 2014).
Immunization Route: Intramuscular injection (i.m.)

Host Response

Mouse Response

Vaccination Protocol: Mice were vaccinated with a single dose of MVA-CHIKV (García-Arriaza et al., 2014).
Vaccine Immune Response Type: VO_0003057
Challenge Protocol: The vaccinated mice were challenged with a high-dose of CHIKV (García-Arriaza et al., 2014).
Efficacy: A single dose of MVA-CHIKV protected all mice after a high-dose challenge with CHIKV (García-Arriaza et al., 2014).

References

García-Arriaza et al., 2014: García-Arriaza J, Cepeda V, Hallengärd D, Sorzano CÓ, Kümmerer BM, Liljeström P, Esteban M. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. Journal of virology. 2014; 88(6); 3527-3547. [PubMed: 24403588].